QLT maintained at neutral by Merrill

QLT Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at neutral on news that the company's reported Visudyne sales for the fourth quarter of 2005 were consistent with Merrill's estimates. The decline of Visudyne sales due to competition in the United State was slightly greater than expected. Shares of the Vancouver, B.C., biopharmaceutical company were down 9 cents, or 1.34%, at $6.64 on volume of 867,587 shares versus the three-month running average of 1,204,820 shares. (Nasdaq: QLTI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.